Last reviewed · How we verify
Intravenous Ketamine Infusions
Intravenous Ketamine Infusions, marketed by Wilderman Medical Clinic, holds a unique position in the treatment landscape due to its direct administration method and established presence in the market. A key strength lies in the protection of its core composition patent, which is set to expire in 2028, providing a significant period of exclusivity. The primary risk is the lack of detailed clinical trial results and revenue data, which may limit the drug's appeal to investors and healthcare providers.
At a glance
| Generic name | Intravenous Ketamine Infusions |
|---|---|
| Sponsor | Wilderman Medical Clinic |
| Modality | Small molecule |
| Phase | FDA-approved |
Approved indications
Common side effects
Key clinical trials
- Electroencephalographic (EEG) Profils for Patients on Intravenous Ketamine.
- Ketamine + Cognitive Training for Suicidality in the Medical Setting (PHASE4)
- Ketamine for Veterans With Parkinson's Disease (PHASE2)
- Ketamine Treatment of Youth Suicide Attempters (PHASE3)
- InTRavenous kEtAmine and immerSive virtUal Reality to Treat dEpression (PHASE3)
- Postoperative Pain Monitoring With ANI in Lumbar Spine Surgery (NA)
- Small Study Comparing Two Pain Medicines in Teenagers for Pain Control After Scoliosis Corrective Surgery. (NA)
- Pilot Study of RR-HNK in OCD (PHASE1, PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Intravenous Ketamine Infusions CI brief — competitive landscape report
- Intravenous Ketamine Infusions updates RSS · CI watch RSS
- Wilderman Medical Clinic portfolio CI